In 2022, Nanoscope Therapeutics initiated a nonrandomized phase I/IIa clinical trial (NCT04919473) aimed at evaluating the safety and beginning to explore the efficacy of an intravitreal injection of an AAV viral vector carrying a multi-characteristic opsin-I (vMCO-I) gene which encodes a light-sensitive ion channel in patients with Stargardt disease due to ABCA4 or other genes. Here, ABCA4 is linked to Stargardt disease.